UCL  IRIS
Institutional Research Information Service
UCL Logo
Please report any queries concerning the funding data grouped in the sections named "Externally Awarded" or "Internally Disbursed" (shown on the profile page) to your Research Finance Administrator. Your can find your Research Finance Administrator at https://www.ucl.ac.uk/finance/research/rs-contacts.php by entering your department
Please report any queries concerning the student data shown on the profile page to:

Email: portico-services@ucl.ac.uk

Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
Publication Detail
Biological treatments for systemic lupus erythematosus
  • Publication Type:
    Journal article
  • Publication Sub Type:
    Article
  • Authors:
    Isenberg D, Leckie MJ
  • Publication date:
    2002
  • Pagination:
    187, 191
  • Journal:
    Scandinavian Journal of Rheumatology
  • Volume:
    31
  • Issue:
    4
  • Print ISSN:
    0300-9742
  • Keywords:
    ACTIVATION, advances, ADVERSE, AGENT, AGENTS, As, Attention, Autoantibodies, B CELL, B CELLS, B-cell, B-CELLS, balance, Biological Products, biological therapy, cell, Cell Transplantation, CELLS, CONTROLLED TRIAL, CONTROLLED TRIALS, COSTIMULATORY MOLECULES, Cyclophosphamide, cytokine, editorial, effects, evaluation, FOCUS, GENE, Genes, hydroxychloroquine, IM, immunology, Immunotherapy, LA, literature, Lupus, Lupus Erythematosus, Systemic, Management, Methotrexate, Molecule, MOLECULES, Patient, patients, Pharmacological, PHYSIOLOGICAL, play, Problems, process, processes, product, production, PRODUCTS, Randomised controlled trial, Randomised Controlled Trials, Recent Advances, Review, Review Literature, ROLES, side effect, side effects, SLE, STATE, STEM, stem cell, stem cell transplantation, STEM-CELL, strategies, strategy, SYSTEMIC, SYSTEMIC LUPUS ERYTHEMATOSUS, SYSTEMIC-LUPUS-ERYTHEMATOSUS, T cell, T cell activation, T-CELL, therapeutic, therapeutic use, THERAPIES, therapy, tolerance, transplantation, treatment, Treatments, TRIAL, TRIALS
  • Notes:
    UI - 22256402 LA - eng RN - 0 (Biological Products) PT - Editorial PT - Review PT - Review Literature DA - 20021008 IS - 0300-9742 SB - IM CY - Norway
Abstract
There have been many recent advances in therapeutic approaches to systemic lupus erythematosus (SLE). The roles of cyclophosphamide, hydroxychloroquine, methotrexate and hormonal treatments in the management of SLE have been investigated in recent randomised controlled trials (1). However, although these pharmacological agents have a role to play in some patients with lupus, broad based effects have led to problems with side effects and adverse reactions. For this reason, more specific therapies are urgently required. Such strategies currently under evaluation include altering the cytokine balance, reducing T cell activation and inducing tolerance, blocking T cell costimulatory molecules, reducing auto-antibody production from B cells, targetting specific genes and stem cell transplantation. These are known as "biological" treatments as their aim is to alter patho- physiological processes occurring in the diseased state. This review will focus on the biological therapies currently under investigation- with particular attention on the cytokine-directed therapies
Publication data is maintained in RPS. Visit https://rps.ucl.ac.uk
 More search options
UCL Researchers
University College London - Gower Street - London - WC1E 6BT Tel:+44 (0)20 7679 2000

© UCL 1999–2011

Search by